{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:26Z","timestamp":1790662766996,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T00:00:00Z","timestamp":1249516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>The anti\u2010Fim response and long\u2010term persistence after vaccination and infection may be of importance in understanding population immunity. Longitudinal serum samples (n\u2003=\u20031330) from 542 non\u2010infected children related to a Swedish vaccine trial showed that the post vaccination (DTPa5) antibody decay curve for pertussis ELISA IgG anti\u2010fimbriae2\/3 (anti\u2010Fim2\/3) was bi\u2010phasic. A slower one followed an initial rapid decay approximately 5\u20136\u2003months after the third dose at 12\u2003months of age. After 71\u2003months, however, 60% still had concentrations above \u22655\u2003EU\/ml, a level that had been shown to correlate with decreased risk of disease. Booster responses after re\u2010vaccination with DTPa5 at 4, 5 and 6\u2003years of age were strong and appeared within 1\u2003week after vaccination, indicating immune memory. Ninety\u2010six young children with verified pertussis infection, for whom we had serum samples both before, during and after the infection, showed a high response if they had been primed with fimbriae (either DTPa5 or DTPwc). In contrast, 76% of infected children not primed with fimbriae (a DTPa2 or DT group) only had concentrations below the minimum level of detection in all samples taken during and after the infection. In two Swedish seroepidemiological surveys, one from 1997 just after reintroduction of universal childhood vaccination against pertussis and one from 2007, the proportion of children 2\u20133\u2003years with anti\u2010Fim2\/3 concentrations &lt;5\u2003EU\/ml was similar and above 90%. This reflects that the two\u2010 or three\u2010component pertussis vaccines (DTPa2 and DTPa3) that were introduced in Sweden in 1996 do not induce anti\u2010Fim2\/3 antibodies. In previous studies it was shown in multivariate analyses that levels of IgG anti\u2010Fim2\/3 <jats:bold>\u2265<\/jats:bold>5\u2003EU\/ml reduced short\u2010term risk of pertussis in small children. As the antibody response to Fim2\/3 after infection is poor in children who have not been primed earlier in life, inclusion of immunogenic Fim2\/3 in future pertussis vaccines should be considered.<\/jats:p>","DOI":"10.1111\/j.1600-0463.2009.02521.x","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T15:56:34Z","timestamp":1249574194000},"page":"660-671","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti\u2010Fim2\/3 antibodies after vaccination and infection"],"prefix":"10.1111","volume":"117","author":[{"given":"HANS O.","family":"HALLANDER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARGARETHA","family":"LJUNGMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAJA","family":"JAHNMATZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANN","family":"STORSAETER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LENNART","family":"NILSSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LENNART","family":"GUSTAFSSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.2.326-382.2005"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4990.454"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/iai.62.3.1118-1120.1994","article-title":"Isotype and antigen specificity of pertussis agglutinins following whole\u2010cell pertussis vaccination and infection with Bordetella pertussis","volume":"62","author":"Mink CM","year":"1994","journal-title":"Infect Immun"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(47)80280-X"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00226-6"},{"key":"e_1_2_7_7_2","unstructured":"CherryJD HeiningerU.Antibody response patterns to Bordetella perussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. American Society for Microbiology 108th General Meeting Boston MA2008."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00227-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1542\/peds.96.6.A48","article-title":"Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines","volume":"96","author":"Meade BD","year":"1995","journal-title":"Pediatrics"},{"key":"e_1_2_7_10_2","first-page":"61","article-title":"WHO Expert Committee on Biological Standardization, 30th Report","volume":"638","author":"WHO","year":"1979","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_2_7_11_2","first-page":"137","article-title":"Essential immunogens in human pertussis: the role of fimbriae","volume":"61","author":"Preston NW","year":"1985","journal-title":"Dev Biol Stand"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(89)90270-3"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602083340602"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06508-2"},{"key":"e_1_2_7_15_2","volume-title":"Ten Year Report. Pertussis Surveillance in Sweden. Progress Report October 1, 1997\u2013December 31, 2007","author":"Carlsson RM GL","year":"2008"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1542\/peds.2005-2746","article-title":"Long\u2010term follow\u2010up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12\u2003months of age indicates the need for a booster dose at 5 to 7\u2003years of age","volume":"118","author":"Gustafsson L","year":"2006","journal-title":"Pediatrics"},{"key":"e_1_2_7_17_2","volume-title":"Vaccinationsuppf\u00f6ljning, Seroepidemiologisk tv\u00e4rsnittsstudie 1997, Slutrapport","author":"Olin P","year":"2004"},{"issue":"2","key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1086\/515056","article-title":"Microbiological and serological diagnosis of pertussis","volume":"28","author":"Hallander HO","year":"1999","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(95)00067-K"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0264-410X(03)00514-0","article-title":"European Sero\u2010Epidemiology Network: standardisation of the assay results for pertussis","volume":"22","author":"Giammanco A","year":"2003","journal-title":"Vaccine"},{"key":"e_1_2_7_21_2","unstructured":"HallanderHO CherryJD GustafssonL StorsaeterJ HeiningerU.Serological correlates of immunity to Bordetella pertussis cough illness. 108th ASM Meeting. Boston MA2008."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00539-3"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1016\/j.vaccine.2005.06.009","article-title":"Pertussis antitoxin decay after vaccination with DTPa: response to a first booster dose 3\u00bd\u20136\u00bd years after the third vaccine dose","volume":"23","author":"Hallander HO","year":"2005","journal-title":"Vaccine"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/S0264-410X(03)00407-9","article-title":"Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis","volume":"21","author":"Storsaeter J","year":"2003","journal-title":"Vaccine"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.031"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.089"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/381439"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.5.838"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/381204"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.6.2856-2865.2005"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.1.47"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/368412"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2009.02521.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0463.2009.02521.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:19:28Z","timestamp":1696983568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2009.02521.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1600-0463.2009.02521.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2009.02521.x","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,19]]},"assertion":[{"value":"2009-08-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}